FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2021065764> ?p ?o ?g. }

• W2021065764 endingPage "909" @default.
• W2021065764 startingPage "902" @default.
• W2021065764 abstract "Aim The aim of this study was to assess the efficacy of Lanreotide Autogel 90 mg PR to prevent lymphorrhea after axillary dissection in breast cancer. Methods A Phase III double-blind, randomized, placebo-controlled trial was performed between April 1st, 2008, and December 31st, 2010. The primary endpoint was the lymphorrhea volume (ml) in the axillary drain during the first four postoperative days. The secondary end points were the number of days until axillary drain removal, hospital stay duration (days), lymphorrhea volume (ml) up to days 15, 30 and 180, number of cases with seroma aspiration and number of seroma aspirations, evaluation of wound, arm pain and mobility on days 15, 30 and 180. Results A total of 148 patients were recruited for the study. Altogether 145 patients were randomized and analysed on an intention-to-treat basis. On the day before surgery 73 patients received the placebo and 72 patients received lanreotide. At four postoperative days, there was a tendency towards a reduction of the lymphorrhea volume in the lanreotide group (median 292 ml, range 1–965 ml) as compared to the placebo group (median 337 ml, range 0–1230 ml), although it was not statistically significant (p = 0.18). There was no significant difference for the secondary end points. In the group with axillary dissection performed alone (n = 24), the lymphorrhea volume was shown to be significantly reduced in the lanreotide group, (p = 0.035) as compared to the placebo group. Conclusion Our study did not identify any overall significant reduction of lymphorrhea on lanreotide." @default.
• W2021065764 created "2016-06-24" @default.
• W2021065764 creator A5001710825 @default.
• W2021065764 creator A5004766713 @default.
• W2021065764 creator A5017372690 @default.
• W2021065764 creator A5029855558 @default.
• W2021065764 creator A5036537174 @default.
• W2021065764 creator A5040024222 @default.
• W2021065764 creator A5048990657 @default.
• W2021065764 creator A5064371345 @default.
• W2021065764 creator A5069412675 @default.
• W2021065764 creator A5090249874 @default.
• W2021065764 date "2012-10-01" @default.
• W2021065764 modified "2023-10-16" @default.
• W2021065764 title "Lanreotide autogel 90 mg and lymphorrhea prevention after axillary node dissection in breast cancer: A phase III double blind, randomized, placebo-controlled trial" @default.
• W2021065764 cites W1979421940 @default.
• W2021065764 cites W1989084443 @default.
• W2021065764 cites W1993618840 @default.
• W2021065764 cites W2013354353 @default.
• W2021065764 cites W2021324210 @default.
• W2021065764 cites W2022493247 @default.
• W2021065764 cites W2047442723 @default.
• W2021065764 cites W2050696992 @default.
• W2021065764 cites W2070115801 @default.
• W2021065764 cites W2074959044 @default.
• W2021065764 cites W2076393520 @default.
• W2021065764 cites W2087285003 @default.
• W2021065764 cites W2088260585 @default.
• W2021065764 cites W2088662114 @default.
• W2021065764 cites W2131719808 @default.
• W2021065764 cites W2138603899 @default.
• W2021065764 cites W2149292038 @default.
• W2021065764 cites W2163662509 @default.
• W2021065764 cites W4235092737 @default.
• W2021065764 doi "https://doi.org/10.1016/j.ejso.2012.05.009" @default.
• W2021065764 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22703757" @default.
• W2021065764 hasPublicationYear "2012" @default.
• W2021065764 type Work @default.
• W2021065764 sameAs 2021065764 @default.
• W2021065764 citedByCount "13" @default.
• W2021065764 countsByYear W20210657642013 @default.
• W2021065764 countsByYear W20210657642014 @default.
• W2021065764 countsByYear W20210657642015 @default.
• W2021065764 countsByYear W20210657642016 @default.
• W2021065764 countsByYear W20210657642018 @default.
• W2021065764 countsByYear W20210657642019 @default.
• W2021065764 countsByYear W20210657642021 @default.
• W2021065764 countsByYear W20210657642022 @default.
• W2021065764 countsByYear W20210657642023 @default.
• W2021065764 crossrefType "journal-article" @default.
• W2021065764 hasAuthorship W2021065764A5001710825 @default.
• W2021065764 hasAuthorship W2021065764A5004766713 @default.
• W2021065764 hasAuthorship W2021065764A5017372690 @default.
• W2021065764 hasAuthorship W2021065764A5029855558 @default.
• W2021065764 hasAuthorship W2021065764A5036537174 @default.
• W2021065764 hasAuthorship W2021065764A5040024222 @default.
• W2021065764 hasAuthorship W2021065764A5048990657 @default.
• W2021065764 hasAuthorship W2021065764A5064371345 @default.
• W2021065764 hasAuthorship W2021065764A5069412675 @default.
• W2021065764 hasAuthorship W2021065764A5090249874 @default.
• W2021065764 hasConcept C121608353 @default.
• W2021065764 hasConcept C126322002 @default.
• W2021065764 hasConcept C141071460 @default.
• W2021065764 hasConcept C142724271 @default.
• W2021065764 hasConcept C168563851 @default.
• W2021065764 hasConcept C202061045 @default.
• W2021065764 hasConcept C203092338 @default.
• W2021065764 hasConcept C204787440 @default.
• W2021065764 hasConcept C27081682 @default.
• W2021065764 hasConcept C2775862295 @default.
• W2021065764 hasConcept C2777433750 @default.
• W2021065764 hasConcept C2779409168 @default.
• W2021065764 hasConcept C2779609023 @default.
• W2021065764 hasConcept C2984496839 @default.
• W2021065764 hasConcept C2991744798 @default.
• W2021065764 hasConcept C42219234 @default.
• W2021065764 hasConcept C530470458 @default.
• W2021065764 hasConcept C71315377 @default.
• W2021065764 hasConcept C71924100 @default.
• W2021065764 hasConcept C81182388 @default.
• W2021065764 hasConceptScore W2021065764C121608353 @default.
• W2021065764 hasConceptScore W2021065764C126322002 @default.
• W2021065764 hasConceptScore W2021065764C141071460 @default.
• W2021065764 hasConceptScore W2021065764C142724271 @default.
• W2021065764 hasConceptScore W2021065764C168563851 @default.
• W2021065764 hasConceptScore W2021065764C202061045 @default.
• W2021065764 hasConceptScore W2021065764C203092338 @default.
• W2021065764 hasConceptScore W2021065764C204787440 @default.
• W2021065764 hasConceptScore W2021065764C27081682 @default.
• W2021065764 hasConceptScore W2021065764C2775862295 @default.
• W2021065764 hasConceptScore W2021065764C2777433750 @default.
• W2021065764 hasConceptScore W2021065764C2779409168 @default.
• W2021065764 hasConceptScore W2021065764C2779609023 @default.
• W2021065764 hasConceptScore W2021065764C2984496839 @default.
• W2021065764 hasConceptScore W2021065764C2991744798 @default.
• W2021065764 hasConceptScore W2021065764C42219234 @default.
• W2021065764 hasConceptScore W2021065764C530470458 @default.
• W2021065764 hasConceptScore W2021065764C71315377 @default.

• next